

Bayesian Modelling of Metabolic Syndrome Risk in AVIS Blood Donors

An analysis of routine laboratory data

Noemi Bongiorno, Martina Caliendo, Davide Marchesi, Greta Minazzi, Elisa Nordera, Matteo Zanetti

Tutor: Simone Colombara

Bayesian Statistics 2025/2026

February 19, 2026



POLITECNICO
MILANO 1863

- ▶ 100,203 laboratory measurements.
- ▶ 4,300 donors - longitudinal data.
- ▶ 5 target variables: Blood pressure, BMI, Glucose, HDL Cholesterol, Triglycerides.

Research question:

Is it feasible to implement a **Metabolic Syndrome screening**, based on AVIS laboratory measurements?
Is this able to identify the predictive biomarkers for high-risk patients and support clinicians in treatment strategies?

Hierarchical multivariate Bayesian model:

$$\mathbf{y}_{ij} \mid \boldsymbol{\mu}_{ij}, \boldsymbol{\Sigma} \stackrel{\text{ind}}{\sim} \mathcal{N}_K(\boldsymbol{\mu}_{ij}, \boldsymbol{\Sigma}), \quad i = 1, \dots, I, j = 1, \dots, n_i$$

$$\boldsymbol{\mu}_{ij} = \mathbf{x}_{ij} \boldsymbol{\beta} + \mathbf{b}_i$$

K : number of target variables (5)

I : number of donors (35)

n_i : number of visits per donor

$\boldsymbol{\beta}$: fixed effects

\mathbf{b}_i : donor specific random intercept

Residual covariance: LKJ

$$\Sigma = \mathbf{L}_\Sigma \mathbf{L}_\Sigma^\top, \quad \mathbf{L}_\Sigma = \text{diag}(\boldsymbol{\tau}) \mathbf{L}_\Omega, \quad \mathbf{L}_\Omega \sim \text{LKJ-Cholesky}(4)$$

$$\tau_k \stackrel{\text{iid}}{\sim} \mathcal{N}^+(0, 0.5)$$

Random effects: Gaussian

$$\mathbf{b}_i = \mathbf{L}_{\Sigma_b} \mathbf{z}_{b_i}, \quad \mathbf{z}_{b_i} \stackrel{\text{iid}}{\sim} \mathcal{N}_K(\mathbf{0}, \mathbf{I}_K)$$

$$\mathbf{L}_{\Sigma_b} = \text{diag}(\boldsymbol{\tau}_b) \mathbf{L}_{\Omega_b}$$

$$\mathbf{L}_{\Omega_b} \sim \text{LKJ-Cholesky}(4)$$



$$\tau_{b_k} \stackrel{\text{iid}}{\sim} \mathcal{N}^+(0, 0.5)$$

Fixed effects: Bayesian Lasso


$$\beta_{pk} \mid \tau_{pk} \stackrel{\text{ind}}{\sim} \mathcal{N}(0, \tau_{pk})$$

$$\tau_{pk} \stackrel{\text{iid}}{\sim} \text{Exponential}\left(\frac{\lambda^2}{2}\right)$$



$$\lambda \sim \text{Gamma}(1, 1)$$



Non-informative:
Basophili_perc
Creatinina
Emoglobina
Ferritina
Ferro_totale
Data
Data_nascita
Rh
ABO
SESSO.



Creatinina and Trigliceridi values of male and females



Idea:

$$\mathbf{b}_i \mid \boldsymbol{\theta}_i \stackrel{iid}{\sim} k(\cdot; \boldsymbol{\theta}_i)$$

$$\boldsymbol{\theta}_i \mid P \stackrel{iid}{\sim} P$$

$$P \sim DP(\alpha, P_0)$$

$k(\cdot; \boldsymbol{\theta}_i)$ is a multivariate Gaussian density

$i = 1, \dots, I$ (35): donor index


Actually:

$$P = \sum_{m=1}^M \pi_m \delta_{\boldsymbol{\theta}_m^*}, \quad \pi_1, \dots, \pi_M : \text{stick-breaking weights}$$

$\boldsymbol{\theta}_m^* = (\boldsymbol{\mu}_m, \boldsymbol{\Sigma}_m)$, $m = 1, \dots, M$ (20): cluster index

$\boldsymbol{\mu}_m \sim \mathcal{N}_K(\mathbf{0}, 2^2 \mathbf{I})$, $\boldsymbol{\Sigma}_m$ with LKJ prior

$K = 5$: number of targets



Cluster-level mean random effects

$$\mu_m =$$


| | PMAX | Glucosio | Trigliceridi | HDL | BMI |
|-----------|--------|----------|--------------|--------|--------|
| Cluster 1 | 4.7929 | 4.5373 | 4.6824 | 3.9904 | 3.2908 |

Covariance matrix of random effects


$$\Sigma_m =$$

| | <i>P</i> | <i>G</i> | <i>T</i> | <i>H</i> | <i>B</i> |
|----------|----------|----------|----------|----------|----------|
| <i>P</i> | 0.0020 | 0.0008 | 0.0014 | −0.0010 | 0.0016 |
| <i>G</i> | 0.0008 | 0.0044 | 0.0015 | −0.0030 | 0.0021 |
| <i>T</i> | 0.0014 | 0.0015 | 0.0856 | −0.0279 | 0.0131 |
| <i>H</i> | −0.0010 | −0.0030 | −0.0279 | 0.0303 | −0.0051 |
| <i>B</i> | 0.0016 | 0.0021 | 0.0131 | −0.0051 | 0.0114 |

Predictive performance: ROC curve



Predictive performance: calibration plot



- ▶ Strong predictive performance.
- ▶ Interpretable associations at the population level.
- ▶ No evidence of latent subgroups: population appears continuous.
- ▶ Flexible hierarchical Bayesian model providing an early risk flag and interpretable biomarkers.

- ▶ Park, T., & Casella, G. (2008). *The Bayesian Lasso*. Journal of the American Statistical Association, 103(482), 681–686.
<https://doi.org/10.1198/016214508000000337>
- ▶ Carvalho, C. M., Polson, N. G., & Scott, J. G. (2010). *The horseshoe estimator for sparse signals*. Biometrika, 97(2), 465–480.
<https://doi.org/10.1093/biomet/asq017>
- ▶ Piironen, J., & Vehtari, A. (2017). *Sparsity information and regularization in the horseshoe and other shrinkage priors*. Electronic Journal of Statistics, 11(2), 5018–5051. <https://doi.org/10.1214/17-EJS1337SI>
- ▶ Yang, S., Rouder, J. N. Assessing Two Common Priors of Covariance in Hierarchical Designs. *OFS*. https://doi.org/10.31234/osf.io/jen65_v2
- ▶ Guglielmi, A. (2025). [Bayesian Statistics Slides]. WeBeep, Politecnico di Milano.

The complete source code and the scripts for this project are available on GitHub at the following repository:

`https://github.com/elisanordera/
Bayesian-Statistics-Project`.